Status:
COMPLETED
A Probiotic Intervention to Prevent Relapse Following Hospitalization for Mania
Lead Sponsor:
University of Texas Southwestern Medical Center
Conditions:
Mania (Neurotic)
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
This will be a 24-week, randomized, double-blind, placebo-controlled trial of adjunctive probiotic therapy in 66 persons hospitalized with a manic or mixed episode. The active study compound will cons...
Detailed Description
Primary Aim 1. To determine if adjunctive probiotic administration can reduce relapse for participants first hospitalized for mania. Hypothesis: Participants receiving adjunctive probiotic microorgani...
Eligibility Criteria
Inclusion
- Capacity for written informed consent
- Currently (or within the last 3 weeks) admitted to inpatient hospital for symptoms of mania.
- Primary Axis I diagnosis (DSM-5) at time of admission of bipolar I (single manic episode, most recent episode manic, or most recent episode mixed) OR schizoaffective disorder, bipolar type (manic or mixed state).
- Proficient in the English language.
- Available to attend follow-up visits.
Exclusion
- Substance- or medically-induced symptoms of mania at time of assessment.
- HIV infection or other immunodeficiency condition (such as receiving cancer chemotherapy).
- A serious medical condition that affects brain or cognitive functioning (e.g., epilepsy, serious head injury, concussion involving loss of consciousness, brain tumor, or other neurological disorder). Note that Hepatitis-C is not an exclusion criterion unless the participant has an acute infection.
- Poorly controlled comorbid medical condition.
- Major surgery in the last year.
- History of weight loss surgery.
- Diagnosis of Intellectual Disability or history of severe learning disorder.
- Diagnosis of alcohol or substance use disorder (moderate/severe) according to DSM-5 criteria within the last 3 months, or has a positive drug toxicity screen proximate to the time of recruitment.
- History of IV drug use.
- Participated in any investigational drug trial in the past 30 days.
- Abnormal electrolyte levels.
- AST and ALT \> 3 times upper limit of normal.
- Pregnant, breastfeeding, or planning to become pregnant during the study period.
- Documented celiac disease (as such persons should be on a gluten-free diet as this is the standard care). Of note, we are not limiting the study to individuals with elevated levels of gliadin or casein antibodies as we intend to look at these levels as a predictor of response.
Key Trial Info
Start Date :
September 6 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 23 2024
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT03383874
Start Date
September 6 2018
End Date
September 23 2024
Last Update
December 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Psychoneuroendocrine Research Program
Dallas, Texas, United States, 75235